ArticleSchizophrenia bulletin2021
Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum.
Article in Schizophrenia bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Mapping symptom-general and symptom-specific targets for transcranial magnetic stimulation in schizophrenia: an electric-field modeling meta-analysis.Molecular psychiatry · 2026Pooled it
- The effects of rTMS over orbitofrontal cortex on cognitive functions in first-episode schizophrenia.Psychological medicine · 2026Trial
- Cognitive rehabilitation with immersive virtual reality in schizophrenia: A randomized waiting list-controlled study.Schizophrenia research. Cognition · 2026Article
- Multiscale characterization of cortical signatures in positive and negative schizotypy: a worldwide ENIGMA study.Molecular psychiatry · 2026Article
- Loneliness, Genetic Susceptibility, Brain Structure, and the Risk of Schizophrenia: A Large Prospective Study.Schizophrenia bulletin · 2026Article
- Local chemoarchitecture explains widespread lower cortical thickness associated with clinical high risk for psychosis.Molecular psychiatry · 2026Article
- Inhibitory control deficits and ventral attention network alterations linked to apathy in schizophrenia.Translational psychiatry · 2026Article
- Data-driven schizophrenia subtyping via brain atrophy trajectories and functional connectivity.Translational psychiatry · 2026Article
- Orbitofrontal Thickness and Network Associations as Transdiagnostic Signature of Amotivation Along the Bipolar-Schizophrenia Spectrum.Schizophrenia bulletin · 2026Article
- Anhedonia in Depressive Disorder and Schizophrenia: An Overview of Causes, Diagnosis, and Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Neurobiological correlates of schizophrenia-specific and highly pleiotropic genetic risk scores for neuropsychiatric disorders.Translational psychiatry · 2025Article
- Comparison of Negative Symptom Network Structures Between Patients With Early and Chronic Schizophrenia: A Network and Exploratory Graph Analysis.Schizophrenia bulletin · 2025Article
- A Hidden Mark of a Troubled Past: Neuroimaging and Transcriptomic Analyses Reveal Interactive Effects of Maternal Immune Activation and Adolescent THC Exposure Suggestive of Increased Neuropsychiatric Risk.Biological psychiatry global open science · 2025Article
- Thinning of the temporal and insular cortex is associated with negative symptoms and impaired attention in Chinese chronic schizophrenia patients with deficit syndrome.BMC psychiatry · 2025Article
- The study on agitation and structure of orbitofrontal cortex subregion in first-episode drug-naïve patients with schizophrenia.Brain imaging and behavior · 2025Article
- Distinct Volume Alterations of Thalamic Nuclei Across the Schizophrenia Spectrum.Schizophrenia bulletin · 2024Article
- Neurostructural subgroup in 4291 individuals with schizophrenia identified using the subtype and stage inference algorithm.Nature communications · 2024Article
- A neuromarker for deficit syndrome in schizophrenia from a combination of structural and functional magnetic resonance imaging.CNS neuroscience & therapeutics · 2023Article
- Basal-Forebrain Cholinergic Nuclei Alterations are Associated With Medication and Cognitive Deficits Across the Schizophrenia Spectrum.Schizophrenia bulletin · 2023Article
- Psychometric properties of the Clinical Assessment Interview for Negative Symptoms (CAINS) in patients with depression and its relationship to affective symptoms.Annals of general psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms such as anhedonia and apathy are among the most debilitating manifestations of schizophrenia (SZ). Imaging studies have linked these symptoms to morphometric abnormalities in 2 brain regions implicated in reward and motivation: the orbitofrontal cortex (OFC) and striatum. Higher negative symptoms are generally associated with reduced OFC thickness, while higher apathy specifically maps to reduced striatal volume. However, it remains unclear whether these tissue losses are a consequence of chronic illness and its treatment or an underlying phenotypic trait. Here, we use multicentre magnetic resonance imaging data to investigate orbitofrontal-striatal abnormalities across the SZ spectrum from healthy populations with high schizotypy to unmedicated and medicated first-episode psychosis (FEP), and patients with chronic SZ. Putamen, caudate, accumbens volume, and OFC thickness were estimated from T1-weighted images acquired in all 3 diagnostic groups and controls from 4 sites (n = 337). Results were first established in 1 discovery dataset and replicated in 3 independent samples. There was a negative correlation between apathy and putamen/accumbens volume only in healthy individuals with schizotypy; however, medicated patients exhibited larger putamen volume, which appears to be a consequence of antipsychotic medications. The negative association between reduced OFC thickness and total negative symptoms also appeared to vary along the SZ spectrum, being significant only in FEP patients. In schizotypy, there was increased OFC thickness relative to controls. Our findings suggest that negative symptoms are associated with a temporal continuum of orbitofrontal-striatal abnormalities that may predate the occurrence of SZ. Thicker OFC in schizotypy may represent either compensatory or pathological mechanisms prior to the disease onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.